title: Effects of raftilose on serum biochemistry and liver morphology in rats fed with normal or high-fat diet.
abstract: Non-alcoholic fatty liver disease is the leading cause of chronic liver injury in developed countries. Oligofructose (OFS) is a prebiotic with proven benefits for health. The aim of the study is to evaluate the effect of 10% OFS on hepatic morphology and lipid metabolism in Wistar Kyoto rats submitted to normal diet (ND) or high-fat diet (FD). Animals were treated for 7 weeks. Lipid profile and serum alkaline phosphatase (ALP) activity were measured and liver histology evaluated at the end of the study. Ten percent OFS reduced triglyceride (TAG) levels when added to any of the diet regimens; 10% OFS decreased plasmatic urea in ND and plasmatic and urinary urea levels in FD; ND + 10% OFS treated rats showed lower ALP activity than controls. FD increased ALP activity, an effect not reversed by OFS. Animals submitted to FD have microscopic hepatic changes: marked steatosis with disarranged centrilobular zone structure; enlarged sinusoids; enlarged mitochondria and an increase in number and volume of adiposomes. Supplementation with 10% OFS in FD reversed those effects. In conclusion, 10% OFS supplementation prevented deleterious effects of FD such as alterations on lipid profile (TAG elevation) and hepatic morphologic changes. OFS decreased ALP activity in animals subjected to ND, which may have contributed to the differences on lipid metabolism.
authors: Institute of Pharmacology & Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
authors: Inês
authors: I
authors: Correia-Sá
authors: Hugo
authors: H
authors: de-Sousa-Lopes
authors: Maria J
authors: MJ
authors: Martins
authors: Isabel
authors: I
authors: Azevedo
authors: Eduardo
authors: E
authors: Moura
authors: Maria A
authors: MA
authors: Vieira-Coelho
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D059305:Diet, High-Fat / Q000009:adverse effects*; D019587:Dietary Supplements; D005234:Fatty Liver / Q000473:pathology; D050356:Lipid Metabolism / Q000187:drug effects*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease; D009844:Oligosaccharides / Q000494:pharmacology*; D056692:Prebiotics; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood; D014508:Urea / Q000097:blood / Q000652:urine
chemical_list: D009844:Oligosaccharides; D056692:Prebiotics; D014280:Triglycerides; C120489:oligofructose; D014508:Urea; D000469:Alkaline Phosphatase
keywords: Alkaline phosphatase; Hepatic; NAFLD; Oligofructose; Raftilose P95®